At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 374 enrolled
Drug / intervention
Asparaginase +8 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
In Brief
A Phase 4 clinical trial evaluating Asparaginase, Cyclophosphamide, and 7 other interventions for Acute Lymphoblastic Leukemia. Completed, enrolled 374 participants across 87 sites.
Detailed Summary
The objective of current protocol is try improve the results of chemotherapy treatment in patients with ALL wich is not indicated the peripheral stem cell transplant in first remission, with an intensive consolidation follow by re-inductions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Lymphoblastic Leukemia
CountriesSpain
Collaborators--
Timeline
Phase 4CompletedFinished
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 1996
Primary CompletionMay 2007
First PostedJul 2007
Study CompletionDec 2007
TodayJul 2026
First PostedJul 2, 2007
Enrollment StartJun 1, 1996
Primary CompletionMay 1, 2007
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 10.9 yearsPosted 19 years ago
Interventions
Asparaginasedrug
Cyclophosphamidedrug
Cytarabinedrug
Daunorubicindrug
Mercaptopurinedrug
Prednisonedrug
Vincristinedrug
Methotrexatedrug
Intrathecally treatmentprocedure